Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | IDH1 |
Variant | mutant |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | IDH1 mutant indicates an unspecified mutation in the IDH1 gene. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05406700 | Phase I | Niraparib | Niraparib In Recurrent IDH 1/2 Gliomas | Recruiting | USA | 0 |
NCT02525692 | Phase II | ONC201 | Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma | Active, not recruiting | USA | 0 |
NCT03557359 | Phase II | Nivolumab | Nivolumab for Recurrent or Progressive IDH Mutant Gliomas | Active, not recruiting | USA | 0 |
NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | 1 |
NCT06095375 | Phase I | Regorafenib + Temozolomide | Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients (REGOMA-2) | Recruiting | ITA | 0 |
NCT02073994 | Phase I | Ivosidenib | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation | Completed | USA | FRA | 0 |
NCT03127735 | Phase I | BAY1436032 | BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML) | Completed | USA | DEU | 0 |
NCT02981940 | Phase II | Abemaciclib | A Study of Abemaciclib in Recurrent Glioblastoma | Active, not recruiting | USA | 0 |
NCT04559230 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab Govitecan in Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT02677922 | Phase Ib/II | Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib | A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Recruiting | FRA | 0 |
NCT04729959 | Phase II | Atezolizumab + Tocilizumab | Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT04015700 | Phase I | GNOS-PV01 + INO-9012 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT05376800 | Phase I | BI 907828 | A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase Ia) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma | Recruiting | USA | ESP | BEL | 0 |
NCT04774393 | Phase Ib/II | Decitabine and Cedazuridine + Ivosidenib + Venetoclax Decitabine and Cedazuridine + Enasidenib + Venetoclax | Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | 0 |
NCT05474378 | Phase I | Retroviral vector transduced B7-H3 CAR T cells | B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme | Recruiting | USA | 0 |
NCT04118036 | Phase II | Abemaciclib + Pembrolizumab | Abemaciclib + Pembrolizumab In Glioblastoma | Withdrawn | USA | 0 |
NCT03430791 | Phase II | Ipilimumab + Nivolumab Nivolumab | Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma | Terminated | USA | 0 |
NCT05183204 | Phase II | GDC-0084 + Metformin | Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma | Recruiting | USA | 0 |
NCT02968940 | Phase II | Avelumab | Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma | Completed | USA | 0 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | GBR | ESP | DEU | AUS | 2 |
NCT03749187 | Phase I | Pamiparib + Temozolomide | BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas (PNOC017) | Recruiting | USA | 0 |
NCT04955938 | Phase I | Enasidenib + Fedratinib Fedratinib + Ivosidenib | A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms | Recruiting | USA | 0 |
NCT05465954 | Phase II | NT-I7 + Pembrolizumab | Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma | Recruiting | USA | 0 |
NCT05222802 | Phase I | ERAS-801 | A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1) | Active, not recruiting | USA | 0 |
NCT02428855 | Phase II | Dasatinib | Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma | Completed | USA | 0 |
NCT05218408 | Phase Ib/II | Cyclophosphamide + Fludarabine CYNK-001 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02) | Withdrawn | 0 | |
NCT05879120 | Phase II | Pembrolizumab | Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma | Not yet recruiting | USA | 0 |
NCT05283109 | Phase I | P30-EPS + Poly ICLC | ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM (ETAPA I) | Recruiting | USA | 0 |
NCT03991832 | Phase II | Durvalumab + Olaparib | Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors (SOLID) | Recruiting | CAN | 0 |
NCT05538572 | Phase I | PRT3645 | A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 1 |
NCT05463848 | Phase II | Olaparib + Pembrolizumab + Temozolomide Pembrolizumab | Surgical Pembro +/- Olaparib w TMZ for rGBM | Recruiting | USA | 0 |
NCT03503409 | Phase II | Ivosidenib | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome | Recruiting | ITA | FRA | 0 |
NCT03207347 | Phase II | Niraparib | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | Completed | USA | 0 |
NCT05052957 | Phase II | Carmustine + Filgrastim + O6-benzylguanine + Temozolomide | hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM) (hSTAR GBM) | Recruiting | USA | 0 |
NCT04945148 | Phase II | Metformin + Temozolomide | Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide (OPTIMUM) | Not yet recruiting | ITA | FRA | 0 |
NCT03047993 | Phase Ib/II | Azacitidine + Telaglenastat | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome | Completed | USA | 0 |
NCT05588141 | Phase Ib/II | Zotiraciclib | Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations | Recruiting | USA | 0 |
NCT02071862 | Phase I | Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat | Study of the Glutaminase Inhibitor CB-839 in Solid Tumors | Completed | USA | 0 |
NCT05432375 | Phase I | Tinostamustine | Study of Tinostamustine for Adjuvant Treatment of Glioblastoma | Active, not recruiting | ESP | 1 |
NCT05743595 | Phase I | Personalized cancer vaccine + Retifanlimab | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | Recruiting | USA | 0 |
NCT04762602 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations | Active, not recruiting | USA | ESP | 0 |
NCT05326464 | Phase III | Tofacitinib | Tofacitinib in Recurrent GBM Patients | Recruiting | USA | 0 |
NCT03158389 | Phase Ib/II | Vismodegib Alectinib Idasanutlin Temsirolimus Atezolizumab Palbociclib APG101 | NCT Neuro Master Match - N²M² (NOA-20) (N²M²) | Completed | DEU | 0 |
NCT03718767 | Phase II | Nivolumab | Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype | Recruiting | USA | 0 |
NCT05401097 | Phase II | Azacitidine + Enasidenib + Venetoclax Azacitidine + Ivosidenib + Venetoclax | IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) | Recruiting | USA | 0 |
NCT04555577 | Phase I | Peposertib Temozolomide | Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma | Recruiting | USA | 0 |
NCT03878095 | Phase II | Ceralasertib + Olaparib | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | Suspended | USA | 0 |
NCT03922555 | Phase I | Decitabine and Cedazuridine | ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas | Recruiting | USA | 0 |
NCT03139916 | Phase II | Bavituximab + Temozolomide | Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma | Completed | USA | 0 |
NCT04629209 | Phase II | ONC201 | A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma | Withdrawn | USA | 0 |
NCT05345002 | Phase II | Retifanlimab + Tretinoin | All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma | Recruiting | USA | 0 |
NCT02492737 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | Completed | USA | FRA | 0 |
NCT02576444 | Phase II | Adavosertib + Olaparib Olaparib Capivasertib + Olaparib Ceralasertib + Olaparib | OLAParib COmbinations (OLAPCO) | Terminated | USA | 0 |
NCT05188508 | Phase II | Olaparib + Pembrolizumab + Temozolomide | Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Recruiting | USA | 0 |
NCT03701295 | Phase Ib/II | Azacitidine + Pinometostat | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | Completed | USA | 0 |
NCT02858895 | Phase II | MDNA55 | Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma | Completed | USA | 0 |
NCT02989857 | Phase III | Ivosidenib | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) | Completed | USA | ITA | GBR | FRA | ESP | 1 |
NCT05756777 | Phase I | Gilteritinib + Ivosidenib Enasidenib + Gilteritinib | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | Recruiting | USA | 0 |
NCT04278781 | Phase II | Ivosidenib | AG-120 in People With IDH1 Mutant Chondrosarcoma | Recruiting | USA | 0 |
NCT06291987 | Phase I | Ivosidenib + Ruxolitinib | Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs (MPN) | Not yet recruiting | USA | 0 |
NCT04195555 | Phase II | Ivosidenib | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | AUS | 1 |
NCT03173248 | Phase III | Azacitidine Azacitidine + Ivosidenib | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUT | AUS | 10 |
NCT05627323 | Phase I | CHM-1101 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | Recruiting | USA | 0 |
NCT04606316 | Phase I | Nivolumab Ipilimumab + Nivolumab | Surgical Nivolumab And Ipilimumab For Recurrent GBM | Active, not recruiting | USA | 0 |
NCT03212274 | Phase II | Olaparib | Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations | Active, not recruiting | USA | 0 |
NCT04396860 | Phase II | Temozolomide Ipilimumab + Nivolumab | Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma | Active, not recruiting | USA | 0 |
NCT05432804 | Phase Ib/II | Selinexor + Temozolomide Temozolomide | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | Suspended | USA | 0 |
NCT04908176 | Phase I | Avapritinib + Midazolam | A Drug-drug Interaction Study of Avapritinib and Midazolam | Recruiting | USA | 0 |
NCT02481154 | Phase I | Vorasidenib | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | 0 |
NCT03220646 | Phase II | Abemaciclib | Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors | Active, not recruiting | USA | 0 |
NCT02632708 | Phase I | Enasidenib + Etoposide + Mitoxantrone Cytarabine + Enasidenib Cytarabine + Idarubicin + Ivosidenib Cytarabine + Daunorubicin + Enasidenib Cytarabine + Enasidenib + Idarubicin Etoposide + Ivosidenib + Mitoxantrone Cytarabine + Ivosidenib Cytarabine + Daunorubicin + Ivosidenib | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation | Active, not recruiting | USA | NLD | DEU | 0 |
NCT06258018 | Phase Ib/II | Niraparib + Temozolomide | Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001) | Not yet recruiting | ITA | 0 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Suspended | USA | NZL | CAN | AUS | 0 |
NCT04764474 | Phase I | HMPL-306 | A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH | Recruiting | USA | ESP | 0 |